SynthesisDrug design, development and therapy2021
Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin - A Promising Natural Lead for New Drug Discovery and Development.
Synthesis in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 61 citations in OpenAlex.
- Quantitative Analysis and Network Pharmacology-Based Profiling of Isolated Metabolites from Swertia purpurascens (D.Don) C.B. Clarke.Journal of separation science · 2026Article
- Integrative Transcriptomics, Machine Learning, and Molecular Dynamics Reveal Honghua Longdan (ACS omega · 2026Article
- Traditional Chinese medicine in diabetes management: a comprehensive review of mechanisms and therapeutic potential.Frontiers in endocrinology · 2026Review
- Swertiamarin fails to induce cytotoxicity in colon cancer cell lines: Evidence against a direct anticancer effect.PloS one · 2026Article
- Iridoids as Multi-target Neuroprotective Agents for Ischemic Stroke: Mechanisms and Therapeutic Potential.Mini reviews in medicinal chemistry · 2026Review
- Review
- Article
- Sweroside: unveiling broad therapeutic potential-from mechanistic insights to clinical potential.Frontiers in pharmacology · 2025Review
- The Therapeutic Effect and Mechanism of Traditional Chinese Medicine in Type 2 Diabetes Mellitus and Its Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- The protective effect ofFrontiers in nutrition · 2025Article
- Genomic characterization of WRKY transcription factors related to secoiridoid biosynthesis in Gentiana macrophylla.BMC plant biology · 2024Article
- Research progress on the natural products in the intervention of myocardial infarction.Frontiers in pharmacology · 2024Review
- Molecular Actions ofAnti-cancer agents in medicinal chemistry · 2024Article
- Cardioprotective Role of Swertiamarin, a Plant Glycoside Against Experimentally Induced Myocardial Infarction via Antioxidant and Anti-inflammatory Functions.Applied biochemistry and biotechnology · 2023Article
- Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation.ACS pharmacology & translational science · 2023Article
- Chromatographic analysis of selected phytosterols fromCurrent research in toxicology · 2023Article
- Anti-inflammatory, analgesic, and antipyretic potential ofFrontiers in pharmacology · 2023Article
- The dual face of microglia (M1/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases.Frontiers in aging · 2023Review
- Therapeutic potential of plant iridoids in depression: a review.Pharmaceutical biology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Swertiamarin, a seco-iridoid glycoside, is mainly found in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.